Xspray Pharma AB (publ)

Stockholm Stock Exchange XSPRAY.ST

Xspray Pharma AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -6.50 M

Xspray Pharma AB (publ) Net Cash Used For Investing Activities is USD -6.50 M for the year ending December 31, 2023, a 49.70% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Xspray Pharma AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -12.93 M, a -10.94% change year over year.
Xspray Pharma AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -11.65 M, a 0.72% change year over year.
Xspray Pharma AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -11.74 M, a -19.90% change year over year.
Xspray Pharma AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -9.79 M, a -85.09% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Stockholm Stock Exchange: XSPRAY.ST

Xspray Pharma AB (publ)

CEO	Dr. Per Andersson Ph.D.
IPO Date	Sept. 28, 2017
Location	Sweden
Headquarters	Råsundavägen 12
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.

Key trends

Past 5 years